Aurinia to acquire Kezar Life Sciences for $6.955 per share

Aurinia agreed to acquire Kezar for $6.955 cash per share plus one non-transferable CVR; the tender offer will commence by April 13, 2026 and the deal requires a majority tender and Kezar closing net cash > $50M, with closing expected in Q2 2026 (Tang Capital ~9% has signed support). Aurinia reported Q4 2025 EPS of $1.53 vs $0.15 expected and revenue of $77.1M vs $74.41M consensus, and named Kevin Tang CEO (no salary/bonuses/equity). Kezar’s zetomipzomib showed steroid-sparing remissions in the PORTOLA Phase 2 autoimmune hepatitis study and Kezar had a Type C FDA meeting aimed at accelerating development.

Analysis

The deal creates a short, predictable arbitrage window for the target’s equity while imposing a medium-term liquidity and execution test on the acquirer. The acquirer’s balance-sheet liquidity and stated discipline matter far more than headline strategic fit: if financing requires asset sales or debt, expect volatility in the acquirer’s equity and potential covenant-driven divestitures that could depress valuation multiples across peers.

Second-order winners include CROs, CMOs and specialty manufacturers tied to expedited autoimmune development — they typically see a step-change in near-term demand if a program is advanced toward pivotal studies. Competitors focused on the same mechanistic niche face compressed optionality values; even a modest acceleration in development timelines can shift licensing leverage and M&A appetite across the sub-sector.

Key tail risks are structural and binary: the tender/closing mechanics and a contingent-payment structure introduce settlement and timing risk measured in quarters-to-years, not days. Regulatory interactions that look constructive at a meeting can still produce more onerous trial requirements; investors should treat clinical readouts as multi-sigma events that can flip sentiment quickly.

Consensus is treating the transaction largely as a financing/fit exercise; the missing piece is the optionality value embedded in the contingent payments and the probability-weighted runway impact on the acquirer. That optionality is asymmetrically skewed — small positive clinical surprises materially re-rate the asset base, whereas financing or closing failures impose a near-immediate mark-down on the acquirer.

Key Decisions for Investors

• Merger-arbitrage long target equity (KZR) through the tender period — horizon: weeks-to-months until close. Risk/reward: capture spread (low-single-digit annualized if clean financing) vs deal-break risk; trim if the acquirer’s liquidity indicators weaken or if major holders revoke support.
• Pair trade: long target (KZR) / short acquirer (AUPH) — horizon: weeks-to-3 months. Rationale: isolates deal convergence while hedging market/regulatory beta; expected return = spread minus funding cost, with downside if the acquirer funds via accretive means or receives positive pipeline readouts.
• Buy downside protection on acquirer (AUPH) via put spreads — horizon: 3–9 months. Size to 2–5% of book; protects against financing dilution or integration shocks while keeping upside from operational beats.
• Tactical long exposure to specialized CRO/CMO names servicing autoimmune immunology trials — horizon: 3–12 months. Small-cap suppliers can outpace peers on accelerating demand; target names with recent capacity and signed capacity agreements to limit execution risk.